Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
The 5-year update of the POLARIX study shows that frontline treatment with polatuzumab vedotin combined with rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) provides a sustained progression-free survival (PFS) benefit compared to the standard R-CHOP regimen in patients with previously untreated intermediate- or high-risk diffuse large B-cell lymphoma (DLBCL).
At a median follow-up of 64.1 months, Pola-R-CHP demonstrated a significant PFS improvement (HR 0.77) with 5-year PFS rates of 64.9% versus 59.1% for R-CHOP.
Although overall survival differences were not statistically significant, exploratory analyses favored Pola-R-CHP in high-risk subgroups, including activated B-cell subtype and higher International Prognostic Index scores.
Long-term safety profiles were comparable between the treatment arms.
These findings support Pola-R-CHP as a new standard of care for frontline DLBCL treatment.